By
Aaron Nicodemus2023-10-25T20:09:00
The head of enforcement at the Securities and Exchange Commission (SEC) outlined the scenarios in which the agency would charge a chief compliance officer for securities law violations.
Gurbir Grewal told an audience of compliance professionals in remarks delivered Tuesday at the New York City Bar Association’s Compliance Institute the agency only brings actions against compliance officers in certain specific situations.
“The short answer is that we do not second-guess good faith judgments of compliance personnel made after reasonable inquiry and analysis. That is why such actions are rare,” he said.
The agency would consider charges in three circumstances, he said:
2024-10-28T21:51:00Z By CW Staff
Gurbir Grewal, who recently left the Securities and Exchange Commission after three years as head of its Division of Enforcement, has joined the law firm Milbank as a partner in its New York office.
2024-05-01T14:00:00Z By Amii Barnard-Bahn
Despite significant issues outside the control of most chief compliance officers, some regulators have signaled more individual liability cases are to be expected. Will accepting the wrong job, in hindsight, make it your last?
2023-11-15T15:46:00Z By Kyle Brasseur
A big year for disgorgement helped the Securities and Exchange Commission to its second highest total of financial remedies ordered in a single year in fiscal year 2023.
2025-11-05T18:35:00Z By Oscar Gonzalez
Approximately $9 billion of potential shadow-banking flows tied to Iranian networks in 2024, according to a new analysis from FinCEN. The report highlights how illicit funds are making their way through financial institutions as they meet the requirements of the Bank Secrecy Act (BSA).
2025-10-31T18:52:00Z By Oscar Gonzalez
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
2025-10-30T19:59:00Z By Oscar Gonzalez
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.
Site powered by Webvision Cloud